ArticleSignal transduction and targeted therapy2025
Vascular dementia: novel insights through multiscale mechanistic modeling.
Qiying Ye, Seongjoon Won, Dongming Cai
Abstract read
In one paragraphArticle in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Seongjoon Won *N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, USA.
Funding
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's DiseaseR01AG068030 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRENNAND, KRISTEN JENNIFER, CAI, DONGMING · 2020 to 2024
$4.2MMolecular Characterization and Validation of Gender Differences in Alzheimers Disease PathogenesisRF1AG054014 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHANG, BIN · 2016 to 2016
$4.2MTranscriptional Control of Neuroinflammation in Alzheimer's DiseaseR01AG072562 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHOU, MING-MING · 2021 to 2025
$4.2MDissect the interplay between sex and APOE at the single cell level to uncover novel pathways, targets and therapeutics for Alzheimer's diseaseRF1AG074010 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHANG, BIN · 2021 to 2021
$3.6MCharacterization of ApoE4 Induced Phospholipid Dysregulation in AD PathogenesisR01AG048923 · NIA · UNIVERSITY OF MINNESOTA · PI CAI, DONGMING · 2015 to 2025
$3.1MDirect protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeuticsR44AG071040 · NIA · ATUX ISKAY GROUP LLC · PI OHLMEYER, MICHAEL · 2024 to 2025
$2.5MResearch Infrastructure for the study of Alzheimer's Disease and Alzheimer's Disease-related dementias in older Asian AmericansUH3AG083258 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Dongming Cai, Clara Li · 2025 to 2026
$2.5MDissect the interplay between sex and APOE at the single cell level to uncover novel pathways, targets and therapeutics for Alzheimer's diseaseR01AG074010 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHANG, BIN · 2024 to 2025
$2.4MCharacterization of ApoE4 Induced Phospholipid Dysregulation in AD PathogenesisRF1AG048923 · NIA · UNIVERSITY OF MINNESOTA · PI CAI, DONGMING · 2021 to 2021
$2.1MResearch Infrastructure for the study of Alzheimer's Disease and Alzheimer's Disease-related dementias in older Asian AmericansUH2AG083258 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, LI, CLARA · 2023 to 2024
$1.2MCharacterization of protective roles of ApoE2 against aging and Alzheimer's diseaseR56AG058655 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, LADU, MARY JO · 2019 to 2019
$841kDirect activators of protein phosphatase 2A (PP2A) as novel Alzheimer's Disease (AD) therapeuticsR43AG071040 · NIA · ATUX ISKAY GROUP LLC · PI OHLMEYER, MICHAEL · 2020 to 2020
$448kBLRD VA I01 BX000593BLRD VA I01 BX003380BLRD VA I01 BX005934NIA NIH HHS R01 AG048923NIA NIH HHS R01 AG068030NIA NIH HHS R01 AG072562NIA NIH HHS R01 AG074010NIA NIH HHS R43 AG071040NIA NIH HHS R44 AG071040NIA NIH HHS R56 AG058655NIA NIH HHS RF1 AG048923NIA NIH HHS RF1 AG054014NIA NIH HHS RF1 AG074010NIA NIH HHS UH2 AG083258NIA NIH HHS UH3 AG083258U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG048923U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG068030U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG071040U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG072562U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG083258U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX003380U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX005934
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID41125608
PMCPMC12546582
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390